Par Pharmaceutical (PRX) Income Statement

Click line-items for a historical chart and %

Revenues:
Net product sales	325.75M
Other product related revenues	6.48M
Total revenues	332.22M
Cost of goods sold	192.48M
Gross margin	139.75M
Operating expenses:
Research and development	28.58M
Selling, general and administrative	54.94M
Settlements and loss contingencies, net	10.1M
Restructuring costs	269K
Total operating expenses	93.89M
Gain on sale of product rights and other
Operating (loss) income	45.86M
Interest income	15K
Interest expense	-39.99M
Income (loss) from continuing operations before provision for income taxes	5.88M
Provision (benefit) for income taxes
Income (loss) from continuing operations
Discontinued operations:
Provision (benefit) for income taxes
(Loss) income from discontinued operations
Net income (loss)	5.44M
Basic earnings (loss) per share of common stock:
Income (loss) from continuing operations
(Loss) income from discontinued operations
Net income (loss)
Diluted earnings (loss) per share of common stock:
Income (loss) from continuing operations
(Loss) income from discontinued operations
Net income (loss)
Weighted average number of common shares outstanding:
Basic
Diluted

Entities mentioned with PRX